YARDLEY, Pa., April 04, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET.
To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.
A replay of the webcast will be available for 30 days following the conclusion of the event.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.
Optinose Investor Contact
Jonathan Neely
This email address is being protected from spambots. You need JavaScript enabled to view it.
267.521.0531
| Last Trade: | US$9.60 |
| Daily Volume: | 0 |
| Market Cap: | US$96.580M |
May 21, 2025 March 26, 2025 January 15, 2025 November 12, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
